Stay updated on Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.4.2 was added, and the notice about a lapse in government funding and operating-status details was removed (the prior notice was v3.4.1).SummaryDifference0.9%

- Check20 days agoChange DetectedThe page version was updated from v3.4.0 to v3.4.1 and a site-wide notice about potential data delays due to a lapse in government funding was added.SummaryDifference0.9%

- Check27 days agoChange DetectedUI and versioning updates include showing the glossary, color-coded highlights, and a new revision label (v3.4.0). These changes do not modify core study data or critical information.SummaryDifference1%

- Check41 days agoChange DetectedA new history revision v3.3.4 was added to the history and the previous revision v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a new revision entry 'Revision: v3.3.3' to the Record History, and removed the 'HHS Vulnerability Disclosure' link along with the 'Revision: v3.3.2' entry from the footer.SummaryDifference0.2%

- Check84 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed in the page history, indicating a minor site version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Nab-Paclitaxel in Metastatic Urothelial Carcinoma Clinical Trial page.